Terms of the deal were not disclosed.
"We are excited to add another renal drug to our expanding pipeline of products,” said Robert L. Chioini, chairman and CEO of Rockwell. “The new bundled-reimbursement for hemodialysis has provided us an ideal opportunity to leverage our existing operating business with more profitable renal products, and we expect this drug, coupled with our current distribution model, will enable us to penetrate the Vitamin-D market effectively. We view this new drug as incrementally positive and accretive in mid-2012."
Calcitriol is an active vitamin-D that is used to treat low levels of calcium in the blood of patients whose kidneys or parathyroid glands are not working normally.
